The Science Journal of the American Association for Respiratory Care

2000 OPEN FORUM Abstracts

Therapeutic Rationale for Single Isomer Beta Agonists

Dean A. Handley Senior Director, Scientific Affairs; Sepracor, Inc

I will address the mystical world of racemic drugs, many of the progressive outcomes in the area of single isomer biology (i.e.: fluoxetine), new developments is single isomer therapy (i.e.: atorvastatin), and the progress in single isomer third generation b agonists of albuterol and formoterol.
I will define the concept of a racemic drug, what respiratory drugs are racemic and why they were marketed as mixtures. We will also recognize the current concerns with use of racemic beta agonists; the most widely used class of asthma drugs, in terms of adverse events and appraise the development of the new class of isomerically pure respiratory drugs.

You are here: RCJournal.com » Past OPEN FORUM Abstracts » 2000 Abstracts » Therapeutic Rationale for Single Isomer Beta Agonists